NCT00314275已完成不适用
Evaluation of Pharmacokinetics (PK) and Safety of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
Medtronic Vascular2 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2006年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 2
- 主要终点
- Pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2, CL, etc.)
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety associated with ABT-578 administered using the Medtronic Endeavor Drug Eluting Coronary Stent system in the treatment of single de novo lesions in native coronary arteries between 2.5 - 3.5 mm in diameter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is at least 18 years of age.
- •The patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional study.
- •The patient is an acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG) surgery.
- •Female patients of childbearing potential must have a negative pregnancy test within 7 days before the procedure.
- •The patient or patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board of the respective clinical site.
排除标准
- •A known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, ticlopidine or clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings, or a sensitivity to contrast media, which cannot be adequately pre-medicated.
- •History of an allergic reaction or significant sensitivity to drugs similar to ABT-578, rapamycin, tacrolimus, everolimus, or any other analog or derivative.
- •A platelet count < 100,000 cells/mm³ or > 700,000 cells/mm³, or a white blood cell (WBC) count < 3,000 cells/mm³.
- •A creatinine level > 2.0 mg/dL within seven days prior to index procedure. Evidence of an acute myocardial infarction within 72 hours of the intended treatment (defined as: Q wave or non-Q wave myocardial infarction having creatine kinase [CK] enzymes greater than or equal to 2 X the upper laboratory normal with the presence of a creatine kinase myocardial-band isoenzyme [CK-MB] elevated above the institution's upper limit of normal).
- •Previous percutaneous coronary intervention (PCI) of the target vessel within 9 months pre-procedure.
- •Planned PCI of any vessel within 30 days post-procedure.
- •During the index procedure, the target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to: cutting balloon, directional coronary atherectomy, excimer laser, rotational atherectomy, thrombectomy, etc.).
- •History of a stroke or transient ischemic attack within the prior 6 months. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months.
- •History of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- •Concurrent medical condition with a life expectancy of less than 12 months. Any previous or planned treatment of the target vessel with anti-restenotic therapies including, but not limited to, brachytherapy.
- •Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires coronary angiography, intravascular ultrasound (IVUS) or other coronary artery imaging procedures.
结局指标
主要结局
Pharmacokinetic parameters (Cmax, Tmax, AUC, T1/2, CL, etc.)
时间窗: 9 months
次要结局
- Success (device, lesion, and procedure)(9 months)
- Major adverse cardiac event (MACE) rate(30 days, 6, 9 and 12 months)
- Target site revascularization (TSR), target vessel revascularization (TVR), and target vessel failure (TVF) rate(9 months)
- For patients receiving overlapping stents at the target lesion: angiographic parameters (in-stent and in-segment), including: late lumen loss(8 months)
- Late loss index(9 months)
- Angiographic binary restenosis (ABR) rate(9 months)
- Minimum luminal diameter (MLD)(9 months)
- Percent diameter stenosis (%DS)(9 months)
- Neointimal hyperplastic volume as measured by intravascular ultrasound (IVUS)(8 months)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese ParticipantsHealthy VolunteersNCT06009237AbbVie24
已完成
1 期
A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) PatientsHepatitis B, ChronicNCT06115993Ausper Biopharma Co., Ltd.129
已完成
1 期
Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With AsthmaAsthmaNCT00986037AbbVie47
已完成
1 期
A Safety and Tolerability Study of ABT-126 in ElderlyAlzheimer's DiseaseNCT00867399Abbott30
已完成
1 期
Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal FunctionRenal ImpairmentNCT02442258AbbVie46